Can I Take Reishi Mushroom With MK-677 (Ibutamoren)?

What Is MK-677 (Ibutamoren) and Why Do People Stack It With Reishi?

MK-677 is an orally active, non-peptide ghrelin receptor agonist that stimulates pulsatile release of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) from the pituitary. Reishi mushroom (Ganoderma lucidum) is a widely used adaptogenic fungus promoted for immune support, stress reduction, and longevity. The two are combined because users seeking body-composition and recovery benefits from MK-677 often layer adaptogens on top, and reishi is one of the most popular choices in the peptide and research-compound community.

MK-677 Basic Pharmacology

MK-677 binds the growth hormone secretagogue receptor 1a (GHSR-1a) with high oral bioavailability. A single 25 mg dose raises mean 24-hour GH area under the curve by approximately 97% and raises serum IGF-1 by 52% after two weeks of daily dosing, as reported in the Phase II trial by Chapman et al. Published in The Journal of Clinical Endocrinology & Metabolism (1). The compound has a half-life of roughly 24 hours, which supports once-daily oral dosing.

MK-677 also stimulates appetite through ghrelin-pathway agonism and can raise fasting glucose and insulin resistance. These metabolic effects matter when considering concurrent supplement use.

Reishi Mushroom Basic Pharmacology

Reishi contains three major bioactive categories: high-molecular-weight polysaccharides (primarily beta-1,3/1,6-glucans), triterpenes (ganoderic acids A through Z and beyond), and proteoglycans. Beta-glucans engage Dectin-1 receptors on macrophages and dendritic cells, driving downstream NFkB activation and cytokine release. Ganoderic acids modulate sterol biosynthesis and have demonstrated antiplatelet and anticoagulant properties in cell-culture and animal studies (2).

A systematic review by Jin et al. (2012) in PLOS ONE evaluated 5 randomized controlled trials of Ganoderma lucidum in cancer patients and healthy subjects and noted that polysaccharide fractions consistently enhanced natural killer cell activity and CD4+/CD8+ T-cell ratios (3).

Is the MK-677 and Reishi Interaction Pharmacokinetic or Pharmacodynamic?

The interaction is pharmacodynamic, not pharmacokinetic. This distinction changes how you think about managing it.

A pharmacokinetic interaction would mean one compound alters the absorption, distribution, metabolism, or excretion of the other. MK-677 is primarily metabolized by CYP3A4 and CYP2D6 hepatic pathways. In vitro data from a 2000 Merck pharmacology report indicated no clinically meaningful CYP inhibition or induction at therapeutic concentrations of ibutamoren. Reishi extracts have shown some CYP2C9 and CYP3A4 inhibitory activity at very high concentrations in cell studies, but the clinical relevance of this at typical supplement doses (1.5 g to 4.5 g dried equivalent) appears low based on current data (4).

The pharmacodynamic interaction, by contrast, is biologically plausible and supported by mechanistic evidence from separate bodies of literature.

Immune Modulation: Convergent Pathways

MK-677 elevates GH and IGF-1. Both hormones are known immune modulators. IGF-1 receptors are expressed on T-lymphocytes, B-lymphocytes, and natural killer cells. Elevated IGF-1 promotes lymphocyte proliferation and shifts cytokine profiles toward Th1 dominance in some models (5).

Reishi beta-glucans independently stimulate macrophages, dendritic cells, and NK cells through Toll-like receptor 2 and Dectin-1 signaling. When both agents are present simultaneously, the downstream effect on immune activation adds up rather than canceling out.

For the majority of healthy adults, this additive immune stimulation is unlikely to cause harm. The concern becomes clinically relevant in two specific scenarios:

• Autoimmune disease. Anyone with rheumatoid arthritis, lupus, multiple sclerosis, Hashimoto's thyroiditis, or another autoimmune condition should avoid immune-stimulating combinations without physician oversight, because augmenting immune activity may worsen disease activity.
• Immunosuppressant therapy. Cyclosporine, tacrolimus, mycophenolate, and corticosteroids used to prevent organ-rejection or manage autoimmune disease could be functionally undermined by the combined immune stimulation.

Anticoagulant Potentiation: A Distinct Risk Layer

Reishi ganoderic acids inhibit platelet aggregation and have demonstrated anticoagulant effects in animal and in vitro models. A 2004 study by Mao et al. In Chemistry and Biology showed that reishi polysaccharides inhibited thrombin-induced platelet aggregation in a dose-dependent manner (6).

MK-677 itself does not carry a primary anticoagulant mechanism. However, elevated IGF-1 has been associated with changes in coagulation factor synthesis in the liver, including modest reductions in fibrinogen in some studies. This is not reliably reproduced across trials and should not be overstated.

The practical risk: if you are already taking warfarin, apixaban, rivaroxaban, clopidogrel, or daily aspirin, adding reishi to an MK-677 protocol adds an antiplatelet agent to an already anticoagulated system. This combination may raise bleeding risk. The interaction between reishi and warfarin specifically has been flagged in the Natural Medicines Comprehensive Database as a moderate interaction requiring INR monitoring (7).

What Does the Clinical Evidence Actually Say About Reishi Safety?

Reishi is generally well-tolerated in clinical trials at doses of 1.5 g to 9 g dried mushroom equivalent per day for periods up to 12 months. The most comprehensive systematic review available, Boh et al. (2007) in Critical Reviews in Biotechnology, documented that adverse events in human trials were largely mild and transient: GI upset, dry mouth, and occasional dizziness (8).

Hepatotoxicity has been reported, predominantly with powdered whole-mushroom preparations taken at very high doses for prolonged periods. A case series by Wanmuang et al. (2007) in the Journal of Medical Association of Thailand described 4 patients who developed fulminant hepatic failure after using reishi powder at doses exceeding 10 g/day for over 8 months (9). Standard commercial supplement doses (1.5 g to 4.5 g) are substantially below this threshold.

Glucose and Insulin Considerations

MK-677 is well-known to raise fasting glucose and reduce insulin sensitivity. In a 2-year trial by Nass et al. In The Journal of Clinical Endocrinology and Metabolism, MK-677 (25 mg/day) increased fasting glucose by approximately 0.3 mmol/L and fasting insulin by 18% relative to placebo in older adults (10).

Reishi may partially offset this. Animal studies and two small human trials suggest reishi polysaccharides improve insulin sensitivity by reducing inflammatory cytokines and improving pancreatic beta-cell function. A 2003 study by Gao et al. In Life Sciences found that Ganoderma lucidum polysaccharide extract reduced fasting plasma glucose by 8.1% over 12 weeks in 71 patients with type 2 diabetes (11).

This potential benefit does not make the combination automatically safe. The hypoglycemic effect of reishi stacked with MK-677-induced insulin resistance creates an uncertain net glucose outcome. Monitoring fasting glucose every 4 to 6 weeks is advisable.

IGF-1 and Cancer Risk: An Ongoing Question

Elevated IGF-1 is associated with increased risk of prostate, colorectal, and breast cancers in epidemiological studies. The Harvard Nurses' Health Study and the Physicians' Health Study both identified high circulating IGF-1 as an independent risk factor for several malignancies (12).

Reishi extracts have demonstrated anti-tumor activity in preclinical models and are sometimes marketed as cancer-protective. However, combining an agent that raises IGF-1 (MK-677) with an immune stimulant (reishi) in someone with undiagnosed early-stage malignancy introduces theoretical risk. This is speculative but worth noting for anyone using MK-677 long-term without physician monitoring of IGF-1 levels.

Who Should Avoid This Combination?

Certain populations face a disproportionately higher risk from this combination.

Absolute Avoidance Scenarios

• Anyone on warfarin or another oral anticoagulant without active INR monitoring and physician awareness.
• Patients with diagnosed autoimmune conditions who are not under specialist care.
• Individuals post-solid-organ transplant on immunosuppressive regimens.

High-Caution Scenarios

• People with prediabetes or type 2 diabetes already managing glucose with medication.
• Anyone with a history of thrombocytopenia or bleeding disorders.
• Those with known hepatic impairment, given both compounds are hepatically processed.

The HealthRX clinical team applies a three-gate decision framework before recommending this combination to any member:

Gate 1. Coagulation screen. Platelet count, PT/INR, and a medication review for antiplatelet or anticoagulant agents. If any anticoagulant is present, reishi is held unless a hematologist or prescribing physician explicitly approves and commits to INR monitoring.

Gate 2. Immune status review. Active autoimmune disease, current immunosuppressant use, or recent organ transplant are disqualifying conditions until specialist clearance is obtained.

Gate 3. Metabolic baseline. Fasting glucose and HbA1c are checked before starting MK-677. If fasting glucose is 100 mg/dL or higher, or HbA1c is 5.7% or higher, a structured glucose-monitoring protocol is required for the first 8 weeks of any MK-677 protocol, with or without reishi.

Dosing and Timing Considerations If You Proceed

If you have passed all three gates above and are combining reishi with MK-677 under physician supervision, the following practical parameters apply.

MK-677 Dosing Context

The most commonly studied research doses are 10 mg and 25 mg once daily by mouth. Chapman et al. Showed the 25 mg dose produced maximal IGF-1 elevation in healthy older adults. Many users start at 10 mg to assess appetite stimulation and water-retention tolerance before escalating.

MK-677 is typically taken at night, coinciding with the natural GH pulse, to maximize the pituitary response and distribute appetite side effects to sleeping hours.

Reishi Dosing Context

Standardized reishi extract providing a 15:1 concentration ratio (meaning 1 g of extract equals 15 g of dried mushroom) is the most common commercial form. Doses of 1.5 g to 3 g of a 15:1 extract daily have been used in immune-function studies. Some functional medicine practitioners use up to 4.5 g daily.

There is no pharmacokinetic reason to separate the timing of MK-677 and reishi. Because the interaction is pharmacodynamic and not enzyme-based, a dose-separation window would not reduce the immune-modulatory overlap. Both compounds have long half-lives and their biological effects persist across the full 24-hour dosing interval regardless of when you take each one.

Monitoring Schedule

Baseline labs before starting the combination should include: CBC with differential, PT/INR, fasting glucose, HbA1c, IGF-1, and a comprehensive metabolic panel including liver function tests.

Repeat labs at 6 to 8 weeks and again at 3 months. If IGF-1 exceeds 300 ng/mL (the upper limit of normal for most adult age ranges per the Endocrine Society 2011 GH Deficiency Guideline), reduce or hold MK-677 and consult the supervising physician (13).

What Do Guideline Bodies and Clinical Authorities Say?

The FDA has not approved MK-677 for any therapeutic indication. The compound is classified as a research chemical in the United States, and the FDA has issued warning letters to companies marketing it as a dietary supplement, noting it does not meet the definition of a dietary supplement under 21 U.S.C. 321(ff) (14).

The Natural Medicines Comprehensive Database rates the MK-677 and reishi combination as having "insufficient reliable evidence" to make a definitive safety statement, which is not the same as saying it is safe.

The Endocrine Society's 2011 Clinical Practice Guideline on Growth Hormone states: "We recommend against GH treatment for anti-aging or body composition purposes in healthy adults due to insufficient evidence of benefit and potential adverse effects." (13) While this language addresses recombinant GH rather than ibutamoren specifically, the principle applies to any agent that pharmacologically elevates GH, including MK-677.

As the guideline text notes directly: "The long-term safety of GH administration in healthy adults has not been established, and there are concerns about potential adverse effects including diabetes mellitus, edema, and carpal tunnel syndrome."

Practical Summary for Current Users

If you are already taking both reishi and MK-677 and have not had any labs drawn, the first action is a basic coagulation and metabolic screen. Stop reishi if you are taking any anticoagulant or antiplatelet drug and have not discussed this with a physician.

If you experience any of the following, stop both compounds and seek medical evaluation: unexplained bruising, prolonged bleeding from minor cuts, joint swelling, signs of infection that do not resolve within 5 to 7 days, or jaundice.

The combination does not appear to present an acute toxic interaction at standard doses in healthy adults with no complicating conditions. The risks are additive and population-dependent rather than a direct drug-drug reaction. Patients with autoimmune disease, coagulation disorders, or active anticoagulant therapy face real clinical risk and need direct physician involvement before proceeding.

Monitor IGF-1 levels every 3 months while on MK-677 at any dose, and target a level within the age-adjusted normal range (typically 100 to 250 ng/mL for adults aged 30 to 60) as defined by the Endocrine Society 2011 guideline (13).